EMA Authorised: Sifrol (pramipexole dihydrochloride monohydrate) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The EMA authorized Sifrol (pramipexole dihydrochloride monohydrate) from Boehringer Ingelheim for restless legs syndrome and Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Restless Legs Syndrome

Drugs mentioned

• Sifrol (ropinirole)

Snippet

Status: Authorised. Therapeutic area: Restless Legs Syndrome;Parkinson Disease. MAH: Boehringer Ingelheim International GmbH. Decision date: 14/03/2024